Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations

R Varela-Fernández, V Díaz-Tomé… - Pharmaceutics, 2020 - mdpi.com
The treatment of the posterior-segment ocular diseases, such as age-related eye diseases
(AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the …

[HTML][HTML] Endophthalmitis

ML Durand - Clinical Microbiology and Infection, 2013 - Elsevier
Endophthalmitis means bacterial or fungal infection inside the eye involving the vitreous
and/or aqueous humors. Most cases are exogenous and occur after eye surgery, after …

Endophthalmitis: a review of current evaluation and management

CA Lemley, DP Han - Retina, 2007 - journals.lww.com
Purpose: To review the current state of evaluation and management of various forms of
endophthalmitis. Methods: A review of the literature is included, encompassing …

Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development

EM Del Amo, KS Vellonen, H Kidron, A Urtti - European Journal of …, 2015 - Elsevier
The aims of this research were to (1) create a curated universal database of intravitreal
volumes of distribution (V ss, ivt) and clearances (CL ivt) of small molecular weight …

Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes

M Edington, J Connolly, NV Chong - Expert opinion on drug …, 2017 - Taylor & Francis
Introduction: The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-
vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment …

Methods for treating inflammation-mediated conditions of the eye

VG Wong, MWL Hu - US Patent 6,726,918, 2004 - Google Patents
Methods for treating in? ammation-mediated conditions of the eye are described,
comprising: implanting into the vit reous of the eye of an individual a bioerodible implant …

Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy

JB Christoforidis, MM Williams, J Wang, A Jiang… - Retina, 2013 - journals.lww.com
Purpose: To determine the anatomic characteristics and pharmacokinetic properties of
intravitreally placed bevacizumab and ranibizumab after pars plana lensectomy or pars …

Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics

A Laude, LE Tan, CG Wilson, G Lascaratos… - Progress in retinal and …, 2010 - Elsevier
This article aims to provide an interpretation and perspective on current concepts and recent
literature regarding the evidence for individualizing intravitreal therapy (IVT), particularly …

Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection

O Artunay, E Yuzbasioglu, R Rasier, A Sengül… - Eye, 2009 - nature.com
Methods This clinical retrospective, non-comparative study included 3022 intravitreal
injections of 1.25 mg bevacizumab consecutively performed for 1822 eyes with exudative …

[图书][B] Endophthalmitis: diagnosis and management.

PJ Lee, DV Seal, GA Payman - 2004 - cabidigitallibrary.org
This book covers every aspect of endophthalmitis, beginning with inflammation and
immunology. The causes of postoperative, post-traumatic and endogenous endophthalmitis …